home / stock / abos / abos news

ABOS News and Press, Acumen Pharmaceuticals Inc. From 07/17/23

Stock Information
Company Name: Acumen Pharmaceuticals Inc.
Stock Symbol: ABOS
Market: NASDAQ
Website: acumenpharm.com
Menu
ABOS ABOS Quote ABOS Short ABOS News ABOS Articles ABOS Message Board
Get ABOS Alerts

News, Short Squeeze, Breakout and More Instantly...
ABOS - Acumen Pharma plans for $100M stock offering, shares fall

2023-07-17 17:27:38 ET Acumen Pharmaceuticals ( NASDAQ: ABOS ) has proposed an underwritten public offering of its common stock to raise $100 million, the company said Monday. All of the shares to be sold in the offering are to be sold by the company. The underwr...
ABOS - Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock

CHARLOTTESVILLE, Va. and CARMEL, Ind., July 17, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s dis...

ABOS - ProMIS, BridgeBio top healthcare gainers; Apellis, Evogene among losers

2023-07-17 10:07:51 ET Gainers: ProMIS Neurosciences ( PMN ) +149% . BridgeBio Pharma ( BBIO ) +62% . Acumen Pharmaceuticals ( ABOS ) +60% . Healthcare Triangle ( HCTI ) +42% . argenx ( ARGX ) +30% . Losers: Apellis P...

ABOS - Acumen stock rallies over 60% on Alzheimer's drug data

2023-07-17 10:00:46 ET Shares of Acumen Pharmaceuticals ( NASDAQ: ABOS ) rallied more than 60% in early trading Monday in the wake of the release of positive data from a Phase 1 clinical trial for its Alzheimer's disease drug candidate ACU193. Acumen shares opened at a $6.11, re...
ABOS - Acumen Pharmaceuticals to Hold Conference Call to Discuss Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer's Disease

CHARLOTTESVILLE, Va. and CARMEL, Ind., July 17, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s dis...

ABOS - Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer's Disease at the Alzheimer's Association International Conference (AAIC) 2023

Topline results from INTERCEPT-AD trial met primary and secondary objectives, demonstrating proof-of-mechanism for ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting antibody Rapid, dose-related, statistically significant (p=0.01) amyloid plaque reduction ob...

ABOS - Acumen Pharmaceuticals: A Risky Bet Through Upcoming Data Readout

2023-07-13 08:03:58 ET Summary Acumen will present Phase 1 topline data on its Alzheimer’s therapeutic candidate, ACU193, at the annual Alzheimer’s Association International Conference. ACU193 is an anti-beta amyloid with a unique binding profile. Results of the ...
ABOS - RDFN, SOS and BDRX among mid-day movers

2023-07-11 13:19:00 ET Gainers: Eloxx Pharmaceuticals ( ELOX ) +112% . CytoMed Therapeutics Limited ( GDTC ) +102% . Biodexa Pharmaceuticals ( BDRX ) +92% . SOS Limited ( SOS ) +39% . Freeline Therapeutics Holdings ( FRLN ) +33% ...

ABOS - CytoMed, Eloxx top healthcare gainers; Journey Medical, ADC Therapeutics among losers

2023-07-11 10:06:43 ET Gainers: CytoMed Therapeutics ( GDTC ) +128% . Eloxx Pharmaceuticals ( ELOX ) +29% . UpHealth ( UPH ) +13% . Virios Therapeutics ( VIRI ) +13% . Acumen Pharmaceuticals ( ABOS ) +9% . Losers: Jou...

ABOS - XPEV, SOS and AOI are among pre market gainers

2023-07-11 08:13:18 ET CytoMed Therapeutics ( NASDAQ: GDTC ) +177% . Dragonfly Energy ( DFLI ) +19% Partners with World’s Largest Teardrop Manufacturer to Provide Full Lithium Power Systems. Acumen Pharmaceuticals ( ABOS ) +17% . Eloxx Pharma...
Previous 10 Next 10